Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
NCT03355976Phase 2Active, not recruiting
- Sponsor
- Brown University
- Start
- Apr 2018
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in clear cell carcinoma (CCC), sponsored by Brown University. Started Apr 2018; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
clear cell carcinoma (CCC)
Beyond the preview
Go deeper on NCT03355976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03355976.